| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Not definitively established. The compound demonstrates antibacterial activity against Gram-positive and Gram-negative bacteria, but the specific molecular target has not been identified. As an anthraquinone derivative, it may act through mechanisms common to this class, including DNA intercalation, inhibition of topoisomerase, or disruption of bacterial membrane function. No specific enzyme or receptor target has been reported in available literature.
|
|---|---|
| ln Vitro |
Lucidin ethyl ether demonstrates antibacterial activity against both Gram-positive and Gram-negative bacteria. In a direct comparative study, lucidin-ω-ethyl ether demonstrated a minimum inhibitory concentration (MIC) of 156 µg/mL against Staphylococcus aureus. The compound is an anthraquinone metabolite isolated from Prismatomeris filamentosa with some antibacterial activity. Quantitative potency data against other bacterial strains are not extensively reported in available literature.
|
| ln Vivo |
No specific in vivo efficacy data are reported for Lucidin ethyl ether in animal models. The compound has been characterized primarily for its in vitro antibacterial activity. No pharmacokinetic, toxicological, or efficacy data in animal models are available. Its primary utility is as a research tool for studying natural product-derived antimicrobial agents.
|
| Enzyme Assay |
Representative protocol: Antibacterial activity is assessed using the microdilution broth method. Test compound is serially diluted in Mueller-Hinton broth in 96-well plates. Bacterial inocula are prepared from overnight cultures and adjusted to a standard density (e.g., 5 × 10^5 CFU/mL). The inoculated plates are incubated at 37°C for 18–24 hours. The minimum inhibitory concentration (MIC) is defined as the lowest concentration of compound that completely inhibits visible bacterial growth, determined by optical density measurement at 600 nm. For Gram-positive bacteria, Staphylococcus aureus is commonly used; for Gram-negative bacteria, Escherichia coli is used.
|
| Cell Assay |
Representative protocol: For cell-based antibacterial assays, bacterial cells are cultured in appropriate media and treated with serial dilutions of test compound. Bacterial growth is monitored by measuring optical density at 600 nm at regular intervals over 18–24 hours. For mammalian cell cytotoxicity, cell lines such as HEK293 or HeLa are plated in 96-well plates and treated with serial dilutions of Lucidin ethyl ether for 24–72 hours. Cell viability is assessed using MTT or resazurin reduction assays. However, no specific mammalian cell assay data have been reported, and the compound's primary activity is antibacterial.
|
| Animal Protocol |
Representative protocol: No established in vivo protocol has been reported for Lucidin ethyl ether. A general approach for evaluating antibacterial compounds in vivo involves using mouse models of systemic or localized bacterial infection. Mice are infected with a lethal or sublethal dose of bacteria (e.g., Staphylococcus aureus or Escherichia coli) via intraperitoneal or intravenous injection. Test compound is administered at various doses and routes (e.g., oral, intraperitoneal) at specified time intervals after infection. Survival rates and bacterial burden in tissues (e.g., blood, liver, spleen) are monitored. However, no such studies have been reported for this compound.
|
| References | |
| Additional Infomation |
According to reports, madder, Indian thorn, and other organisms with available data contain leucine ether.
|
| Molecular Formula |
C17H14O5
|
|---|---|
| Molecular Weight |
298.29006
|
| Exact Mass |
298.084
|
| CAS # |
17526-17-9
|
| PubChem CID |
28578
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.409g/cm3
|
| Boiling Point |
540.6ºC at 760 mmHg
|
| Flash Point |
203.7ºC
|
| Vapour Pressure |
2.67E-12mmHg at 25°C
|
| Index of Refraction |
1.662
|
| Source |
Originated from plants: Rubiaceae Prismatomeris filamentosa Craib
|
| LogP |
2.409
|
| tPSA |
83.83
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
22
|
| Complexity |
448
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCOCC1C(O)=CC2C(C3=CC=CC=C3C(=O)C=2C=1O)=O
|
| InChi Key |
VRARPPQMEQUQET-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H14O5/c1-2-22-8-12-13(18)7-11-14(17(12)21)16(20)10-6-4-3-5-9(10)15(11)19/h3-7,18,21H,2,8H2,1H3
|
| Chemical Name |
2-(ethoxymethyl)-1,3-dihydroxyanthracene-9,10-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3524 mL | 16.7622 mL | 33.5244 mL | |
| 5 mM | 0.6705 mL | 3.3524 mL | 6.7049 mL | |
| 10 mM | 0.3352 mL | 1.6762 mL | 3.3524 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
